Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD

Lei Lei Wu

News Reporter

Decades ago, Amber Salzman remembers feeling like there was nothing she could do to help her cousin-in-law with a progressive muscle disease called facioscapulohumeral muscular …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Marks’ exit at FDA rattles an already teetering biotech industry

Lilly's heart disease drug could be dosed as little as once a year, study shows

Inspirna, which was preparing for a Phase 3 cancer trial, has folded

What’s next after Marks? At FDA, questions over more top exits and future vision for drug agency

Alphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Epi­crispr rais­es $68M, will start clin­i­cal tri­al of epi­ge­net­ic edit­ing for FSHD

News Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD